Expanded Access Program for Revumenib

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
Syndax Pharmaceuticals
Study ID
NCT05918913
Status
No Longer Available

Conditions

  • Relapsed/Refractory Acute Leukemia

Eligibility Criteria

Sex
ALL
Age
6 Months - N/A
Healthy Volunteers
Not accepted

Interventions

  • Revumenib — DRUG
    Revumenib administered orally every 12 hours.

Study Details

This expanded access program will provide an investigational treatment option in a controlled clinical setting for participants who are not otherwise eligible to participate in other Syndax-sponsored clinical studies and have no approved treatment options.

Key Dates

First listed
Jun 26, 2023
Status verified
Aug 2025

Locations (35)

FacilityCityStateZIPSite coordinators
Alabama Center for Childhood Cancer And Blood Disorders, Children's of AlabamaBirminghamAlabama35233-
Phoenix Children's HospitalPhoenixArizona85016-
City of HopeDuarteCalifornia91010-
City of Hope at Orange County Lennar Foundation Cancer CenterIrvineCalifornia92618-
UCLA, UCLA RRMC, Drug Information Center, Department of Pharmaceutical Services Drug Supply ShipmentLos AngelesCalifornia90095-
Lucile Packard Children's Hospital-StanfordPalo AltoCalifornia94304-
Rady Children's HospitalSan DiegoCalifornia92123-
University of California, San FranciscoSan FranciscoCalifornia94158-
Center for Cancer and Blood Disorders, Colorado Children's HospitalAuroraColorado80045-
HCTU, Division of Hematology, University of Colorado, Anschutz Medical CenterAuroraColorado80045-
Advent Health OrlandoOrlandoFlorida32804-
Children's Healthcare of AtlantaAtlantaGeorgia30322-
Winship Cancer Institute at Emory UniversityAtlantaGeorgia30322-
Lurie Children's Hospital of ChicagoChicagoIllinois60611-
University of Chicago Medical CenterChicagoIllinois60637-
University of Iowa Hospitals and ClinicsIowa CityIowa52242-
Children's HospitalNew OrleansLouisiana70118-
Dana-Farber Cancer Institute, Boston Children's Cancer and Blood Disorders CenterBostonMassachusetts02215-
Children's Mercy Hospital-Kansas CityKansas CityMissouri64108-
Siteman Cancer Center - Washington UniversitySt LouisMissouri63110-
Hackensack University Medical CenterHackensackNew Jersey07601-
Memorial Sloan Kettering Cancer CenterLong Island CityNew York10065-
Montefiore Medical CenterThe BronxNew York10467-
Duke University Medical CenterDurhamNorth Carolina27705-
Cincinnati Children's Hospital Medical CenterCincinnatiOhio45229-
Division of Hematology and Oncology, Division of Pulmonary, Critical Care and Sleep Medicine, Vontz Center for Molecular StudiesCincinnatiOhio45267-
OSU Medical CenterColumbusOhio43210-
Doernbecher Children's Hospital, Oregon Health & Science UniversityPortlandOregon97239-
Children's Hospital of PhiladelphiaPhiladelphiaPennsylvania19104-
St. Jude Children's Research HospitalMemphisTennessee38105-
MD Anderson Cancer CenterHoustonTexas77030-
Memorial Hermann-Texas Medical CenterHoustonTexas77030-
Texas Children's HospitalHoustonTexas77030-
Division of Hematology and Hematologic Malignancies, University of Utah-Huntsman Cancer HospitalSalt Lake CityUtah84112-
Seattle Children's Research Institute, Seattle Childrens HospitalSeattleWashington98105-

Find similar trials in Birmingham, AL